|
2. ETIOLOGIE
|
|
|
FDA: Irbesartan lots recalled over likely carcinogen [UPI]
|
|
|
|
|
|
Prinston Pharmaceutical, doing business as Solco Healthcare, has voluntarily recalled of eight more lots of irbesartan blood pressure medication after detecting trace amounts of impurity in an active pharmaceutical ingredient, the Food and Drug Administration announced Friday.
|
|
|
|
|
|
|
3.1.1 PRÉVENTION - TABAC - E-CIGS
|
|
|
|
4.12 BIOPSIES LIQUIDES
|
|
|
How new tests might help find treatments for cancers with no known origin [Cancer Research UK]
|
|
|
|
|
|
“In Manchester, we are profiling a lot of patients as part of one of our academic trials called TARGET,” Cook says. “We are taking blood tests from patients, analysing the DNA in the blood and looking at whether there are any molecular changes in that DNA related to the cancer. We can then see whether there is an existing drug we have access to that targets that molecular change.”
|
|
|
|
|
|
|
|
4.7 DÉP., DIAG. & PRONO. - COL DE L'UTÉRUS
|
|
|
|
5.10 TRAITEMENTS - ESSAIS
|
|
|
|
|
5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS
|
|
|
Celgene strikes Obsidian deal to boost CAR-T options [Fierce Biotech]
|
|
|
|
|
|
Obsidian thinks the immunomodulatory factors can enhance adoptive cell therapies but only if they are closely controlled. To achieve such control, Obsidian has designed small, fully human protein domains that facilitate regulation of the expression of transduced genes by small molecules.
|
|
|
|
|
|
|
|
|
5.12.6 IMMUNOTHÉRAPIES - AMM
|
|
|
|
5.2 PHARMA
|
|
|
|
|
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
|
5.5.5 ASCO (GASTRO-INTESTINAL)
|
|
|
|
|
6. LUTTE CONTRE LES CANCERS
|
|
|